Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer

  • Authors:
    • Gabriela Sofía Gómez‑Macías
    • María Lourdes Garza‑Rodríguez
    • Raquel Garza‑Guajardo
    • Daniela Monsiváis‑Ovalle
    • Jesús Ancer‑Rodríguez
    • Hugo Alberto Barrera‑Saldaña
    • Oralia Barboza‑Quintana
  • View Affiliations

  • Published online on: May 16, 2018     https://doi.org/10.3892/ol.2018.8714
  • Pages: 1073-1078
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metalloproteinase matrix 11 (MMP11) is a member of the matrix metalloproteinase family, which are able to degrade extracellular matrix components, and may serve a central function in the enhancement of tumor‑induced angiogenesis, cell migration, proliferation, apoptosis and connective tissue degradation. In the present study, MMP11 gene expression was investigated using the reverse transcription‑polymerase chain reaction in 68 cases of type I endometrial carcinoma, and all data were analyzed in association with clinical characteristics. Overexpression of MMP11 was demonstrated in 75%, and sub‑expression was demonstrated in 25%, of endometrial cancer cases. Sub‑expression cases were associated with good histological parameters, including low histological grade (G1 and G2), early pathological stage, and absence of vascular invasion, metastasis and recurrence. In total, 76.4% of endometrial cancer cases with sub‑expression were identified as early stage 1A and B; however, 23.6% of cases were identified as stage 2, with vascular invasion present in 29.4% of cases. On the other hand, cases which demonstrated overexpression with high ranges (>10 times more than control) were associated with adverse histopathological characteristics, including high grade tumor (G3) and vascular invasion. In conclusion, the increased expression of MMP11 may be used as a prognostic biomarker in patients with type 1 endometrial cancer.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gómez‑Macías GS, Garza‑Rodríguez ML, Garza‑Guajardo R, Monsiváis‑Ovalle D, Ancer‑Rodríguez J, Barrera‑Saldaña HA and Barboza‑Quintana O: Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer. Oncol Lett 16: 1073-1078, 2018
APA
Gómez‑Macías, G.S., Garza‑Rodríguez, M.L., Garza‑Guajardo, R., Monsiváis‑Ovalle, D., Ancer‑Rodríguez, J., Barrera‑Saldaña, H.A., & Barboza‑Quintana, O. (2018). Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer. Oncology Letters, 16, 1073-1078. https://doi.org/10.3892/ol.2018.8714
MLA
Gómez‑Macías, G. S., Garza‑Rodríguez, M. L., Garza‑Guajardo, R., Monsiváis‑Ovalle, D., Ancer‑Rodríguez, J., Barrera‑Saldaña, H. A., Barboza‑Quintana, O."Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer". Oncology Letters 16.1 (2018): 1073-1078.
Chicago
Gómez‑Macías, G. S., Garza‑Rodríguez, M. L., Garza‑Guajardo, R., Monsiváis‑Ovalle, D., Ancer‑Rodríguez, J., Barrera‑Saldaña, H. A., Barboza‑Quintana, O."Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer". Oncology Letters 16, no. 1 (2018): 1073-1078. https://doi.org/10.3892/ol.2018.8714